adminChemistry R&D and procurement teams sourcing (S)-5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-N-methyl-N-phenyl-1H-indole-2-carboxamide (CAS 2212021-79-7) are usually engaged in advanced heterocyclic synthesis and scaffold development work. This indole-2-carboxamide scaffold is a specialized chiral building block widely studied within GLP‑1 related small‑molecule chemistry research.
As an early-stage intermediate in a multi-step synthetic sequence, its quality and process consistency directly influence downstream reaction yields, impurity profiles and analytical validation workflows. This article covers key evaluation criteria for buyers sourcing this chiral intermediate, and introduces how Shandong Tianming Pharmaceutical Group addresses common bottlenecks in specialty fine chemical supply.
The Chemical Profile of CAS 2212021-79-7
(S)-5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-N-methyl-N-phenyl-1H-indole-2-carboxamide is recognized as a core indole‑2‑carboxamide scaffold in a series of GLP‑1 related synthetic research routes. It is one of a set of structurally defined intermediates, positioned between early chiral building blocks and advanced downstream intermediates such as nitrile precursor CAS 2212021-81-1 and amidoxime intermediate CAS 3047556953. Demand for this scaffold and its related derivatives mainly comes from chemistry laboratories and process development teams conducting synthetic route exploration, impurity methodology development and analytical method validation.
Core Challenges When Sourcing This Niche Chiral Intermediate
Buyers searching for low-volume, structurally complex heterocyclic intermediates like CAS 2212021-79-7 frequently encounter similar operational hurdles:
- Long lead times for custom chiral synthesis;
- Fluctuating cost of premium starting raw materials;
- Batch-to-batch inconsistency that disrupts continuous lab and pilot work;
- High coordination overhead when assembling a synthetic sequence from multiple separate vendors.
For chiral scaffolds with strict enantiomeric control requirements, matching consistent process parameters is especially challenging. Many general chemical suppliers can provide catalog quotations, yet lack deep process knowledge to support method transfer and impurity tracing. Working with a supplier that maintains a connected portfolio of related intermediates can greatly reduce the workload of repeated vendor qualification for a single synthetic sequence.
Full-Series Intermediate Portfolio for GLP‑1 Related Synthetic Research
Shandong Tianming Pharmaceutical Group develops a connected intermediate product line covering key nodes for GLP‑1 scaffold chemistry research, from foundational heterocyclic starting materials to advanced functionalized intermediates. Alongside CAS 2212021-79-7, the product matrix includes:
- 5-bromo-4-fluoro-1-methyl-1H-indazole (CAS 1784678-61-0)
- (S)-5-cyano-4-hydroxy-6-methyl-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (CAS 3047293-07-9)
- Indole N‑alkylation intermediate (CAS 2212021-80-0)
The group also supplies matching impurity reference standards for analytical testing and method development, supporting customers’ in-house characterization work together with bulk intermediate supply. This integrated product layout helps buyers simplify multi-component sourcing and streamline cross-batch data alignment.
Quality Control Specifications & Analytical Infrastructure
Tianming Pharmaceutical applies strict control standards for its GLP‑1 research intermediate series:
- Single individual impurity: below 0.1%
- Total impurities: below 0.5%
- Enantiomeric impurity: below 0.1%
- Assay: ≥98.0%
Quality control runs through the full workflow, from incoming raw material inspection, in-process monitoring to final product release. The company has invested more than RMB 40 million in analytical hardware, including HPLC, GC, MS, LC‑MS and chiral chromatography instruments, to verify purity, impurity distribution and chiral consistency across batches.
Process Development & Scalable Production Capacity
Independent process development and multiple rounds of route optimization have been completed for this intermediate series, with scalable synthetic procedures suitable for scale-up from lab to pilot and larger production batches.
Tianming Pharmaceutical operates three coordinated production sites with over 160 reactor units, with total portfolio capacity reaching hundreds of tons annually. Safety stock planning and flexible capacity scheduling are available to support fluctuating R&D order volumes. Two R&D centers are located in Jinan and Nanjing, with combined laboratory space exceeding 6,000 m² and an in-house technical team of more than 100 chemists and analysts. Annual R&D investment accounts for over 10% of revenue, with additional resources allocated to quality management system iteration.
Flexible Supply: Gram, Kilogram to Bulk Order Support
The company supports flexible order sizes to match different R&D stages: gram-scale lab trial, kilogram pilot batches and larger custom production.
- In-stock items: 7–15 working days lead time, covering order confirmation, QC review, packaging and shipment
- Custom synthesis: lead time depends on synthetic complexity, workshop schedule and raw material availability
- Expedited production scheduling is available for time-sensitive R&D projects upon request.
Technical Documentation Package for Lab & Analytical Work
Beyond chemical material supply, R&D teams require supporting documentation to carry out process validation and analytical studies. Available deliverables include full COA, analytical methodology descriptions, impurity profile data and stability study records. Digital management systems including CRM, ERP and BPM are deployed to support order tracking, inventory control, production scheduling and end-to-end batch traceability.
Dual-Technical Support & Logistics Service
Procurement of specialty chiral intermediates relies heavily on fast, precise technical communication. Tianming Pharmaceutical adopts a dual support model: dedicated account manager + process engineer for each project.
- Standard technical enquiries: reference feedback within 2 hours
- Complex process & analytical questions: formal written report within 24 hours
- On-site technical discussion and periodic follow-up can be arranged for framework and bulk cooperation clients. Transport insurance is included for all shipments. Compensation and replacement arrangements apply for quality damage caused by transit. Cold-chain logistics with temperature logging are offered for temperature-sensitive materials.
Closing Takeaways for R&D Procurement
When evaluating suppliers for CAS 2212021-79-7, procurement teams should look beyond unit price. Key evaluation points include whether the supplier can provide a connected chain of related synthetic intermediates, stable impurity and chiral control, scalable capacity matching your project roadmap, and complete technical documentation for analytical work. Shandong Tianming Pharmaceutical Group, operating under the brand Tianming Pharmaceutical, provides this full intermediate portfolio backed by integrated R&D-production infrastructure, three production bases and systematic quality management for fine chemical research materials.
Disclaimer All products described are fine chemical intermediates for laboratory research and synthetic exploration only. The materials are not intended for human or animal clinical use, drug formulation, or any commercial pharmaceutical application. No representation or guarantee is made regarding freedom to operate under any third-party patent rights. Buyers shall independently verify patent clearance and compliance for their own intended use.
Tianming Pharmaceutical Group